NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

The end point was not “buried” in the interim blinded data. They addressed PFS, and how they intend to approach it when they unblind the data, which is when, as you know, it counts.

The study’s primary endpoint is PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon.